Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
1
Capitalist Slides
Hearing Loss and the Healthcare system
Nicholas S. Reed, AuD
Assistant Professor │ Dept. OtolaryngologyCore Faculty │ Cochlear Center for Hearing and Public Health
Johns Hopkins UniversityBaltimore, Maryland
2
Capitalist Slides
Prevalence of Hearing Loss in the United States, 2001-2008
Hearing loss defined as a better-ear PTA of 0.5-4kHz tones > 25 dB
Lin et al., Arch Int Med. 2011
3
Capitalist Slides
Hearing Loss and Health Aging
Lin JAMA 2014
Maintaining Physical Mobility & Activity
Cognitive Vitality & Avoiding Dementia
Avoiding Injury
Health ResourceUtilization
Keeping Socially Engaged & Active
4
Capitalist Slides
Hearing Loss & Hearing Aid UsePrevalence in the U.S. 1999-2006
Chien, W. Arch Int Med. 2012
5
Capitalist Slides
Hearing Loss: Primer
6
Capitalist Slides
Hearing Loss: Primer
7
Capitalist Slides
“You should go to the pharmacy before you get to your house.”
Hearing Loss: Primer
“You should go to the pharmacy before you get to your house.”
8
Capitalist Slides
Patient-Provider Communication
Shukla et al. 2018 AM J Med Qual; IOM 2001; Cohen et al. (2017) JAGS; Cudmore et al (2017) JAMA-OTO
IOM 2001: Patient-provider care is cornerstone of patient-centeredcare “…care that is respectful of and responsive to individual patient
preferences, needs, and value”
Only 23.9% (16/67) of patient-provider communication papersinvolving older adults included any mention of hearing loss Of those 16, only 4 included hearing loss in analyses
Systematic review of inpatient patient-provider communication 13/13 studies that included hearing loss found it associated with
poorer patient-provider communication
9
Capitalist Slides
Patient-Provider Communication
Shukla et al. 2018 (under review); IOM 2001
Patient-provider communication impacts healthcare metrics quality of care time to diagnosis length of stay treatment adherence satisfaction with care
Hearing Loss
Healthcare metrics?
10
Capitalist Slides
Objectives of Talk
Part 1; Secondary Analyses Hearing Loss and satisfaction: Cross sectional analyses The impact of hearing loss on health care cost and utilization
measures
Part 2; Primary Data Development and feasibility investigation of a systematic strategy to
address hearing loss in the inpatient setting
11
Capitalist Slides
Secondary AnalysisSatisfaction - Methods
Reed et al. (2018) JAGS (in press); Reed et al. 2018 (in-prep)
Data Sources:
Medicare Current Beneficiaries Survey 2015 Sample weighted national sample of 12311 US Medicare
Beneficiaries Interview conducted survey (8% respond by proxy)
Atherosclerosis Risk in Communities Study Objective audiometry pilot offered to ~300 persons Washington County, MD site
12
Capitalist Slides
Secondary AnalysisSatisfaction - Methods
Reed et al. (2018) JAGS (in press); Reed et al. 2018 (in-prep)
Exposure: Hearing Loss
Medicare Current Beneficiary Survey No trouble hearing A little trouble hearing A lot of trouble hearing If applicable: w/ hearing aid
Atherosclerosis Risk in Communities Objective pure-tone audiometry Conducted in sound booth with calibrated equipment Pure-tone average (speech frequency sounds) Defined according to W.H.O criteria
Functional Hearing Loss
Objective Hearing Loss
13
Capitalist Slides
Secondary AnalysisSatisfaction - Methods
Reed et al. (2018) JAGS (in press); Reed et al. 2018 (in-prep)
Outcome: Self-report satisfaction
Medicare Current Beneficiaries Survey: “Please tell me how satisfied you have been with the following:
The overall quality of the health care [you have] received [overthe past year/since (reference date)].”
Very Satisfied, Satisfied, Dissatisfied, Very Dissatisfied
Atherosclerosis Risk in Communities: “Overall, how satisfied are you with the quality of care you
received from your healthcare providers over the past 12months?”
Very Dissatisfied, Somewhat Dissatisfied, Somewhat Satisfied,Very Satisfied
14
Capitalist Slides
Secondary AnalysisSatisfaction - Methods
Reed et al. (2018) JAGS (in press); Reed et al. 2018 (in-prep)
Outcome: Self-report satisfaction
Medicare Current Beneficiaries Survey: “Please tell me how satisfied you have been with the following:
The overall quality of the health care [you have] received [overthe past year/since (reference date)].”
Very Satisfied, Satisfied, Dissatisfied, Very Dissatisfied
Atherosclerosis Risk in Communities: “Overall, how satisfied are you with the quality of care you
received from your healthcare providers over the past 12months?”
Very Dissatisfied, Somewhat Dissatisfied, Somewhat Satisfied,Very Satisfied
15
Capitalist Slides
Secondary AnalysisOdds Dissatisfaction With Care
Reed et al. (2018) JAGS (in press); Reed et al. 2018 (in-prep)
Note: Logistic Regression model includes age, sex, race, income, education level, general health, functional limitations, and martial status; Sensitivity Analyses using ordinal logistic and excluding disabled led to similar results
Self-Report Difficulty Hearing
Total N(unweighted)
Total N(weighted)
Dissatisfied with Care
Odds Ratio [95% CI] P-Value
No Trouble Hearing 5915 26.1 million 3.10% REF
A little Trouble Hearing 4667 19.3 million 4.64% 1.47
[1.06-2.03] 0.021
A Lot of Trouble Hearing
865 3.2 million 6.52% 1.74[1.15-2.62] 0.009
Total 11447 48.6 Million 3.94% - -
Medicare Current Beneficiaries Survey:
16
Capitalist Slides
Secondary AnalysisOdds Dissatisfaction With Care
Reed et al. (2018) JAGS (in press); Reed et al. 2018 (in-prep)
Note: Logistic regression model for odds of less than optimal satisfaction and hearing loss adjusted for age, sex, global cognitivescore, comorbidity count (diabetes, hypertension, myocardial infarction, asthma, cancer, stroke, and hospital stay).
Atherosclerosis Risk in Communities:
75-year-old participant: Every 10 dB increase in
HL, odds of < satisfiedincreased .94 (95%CI:0.74-1.20).
85-year-old participant: Every 10 dB increase in
HL, odds of < satisfiedincreased 1.33 (95%CI:0.96-1.83).
17
Capitalist Slides
Objectives of Talk
Part 1; Secondary Analyses Hearing Loss and satisfaction: A cross sectional analysis The impact of hearing loss on health care cost and utilization
measures
Part 2; Primary Data Development and feasibility investigation of a systematic strategy to
address hearing loss in the inpatient setting
18
Capitalist Slides
Secondary AnalysisCost/Utilization - Methods
Reed et al. (2018) JAMA-OTO
Data Source:
OptumLabs® Data Warehouse (Jan 1, 2000 to Dec 31, 2014)
125 million de-identified data claims from across US
Private and Medicare Advantage
Physician, hospital, prescription claims information
Socioeconomic and satisfaction measures (survey)
19
Capitalist Slides
Secondary AnalysisCost/Utilization - Methods
Reed et al. (2018) JAMA-OTO
Outcome Variables:
1. Medical Costs Total
Health plan paid Out of Pocket Isolated to hearing loss
2. Number inpatient hospitalizations3. Total days hospitalized4. Number of readmissions with 30-days of discharge5. Number Emergency Department Visits6. Number of days with at least one outpatient visit
20
Capitalist Slides
Secondary AnalysisCost/Utilization - Methods
Reed et al. (2018) JAMA-OTO
Exposure Variable:
Evidence of Hearing Loss from ICD codes ≥ 50 years No hearing aid usage evidence from ICD codes No hearing loss ICD code two years prior to index date Included
ICD codes for hearing loss and/or sensorineural hearingloss
Excluded ICD hearing codes such as sudden, hyperacusis, neural,
conductive, central, etc. Persons with same year code related to ear disease such as
otorrhea, otalgia
21
Capitalist Slides
Secondary AnalysisCost/Utilization - Methods
Reed et al. (2018) JAMA-OTO
Sample:
Propensity matched (1:1) to those with evident hearing loss to thosewithout any evidence of hearing loss (at any point)
Matching variables Insurance type Demographic (Age, Sex, Education, Income) Census geographic region Education level Charlson comorbidty index Number of office visits, inpatient stays, ED visits Dementia, depression, stroke, cancer (breast, prostate, renal
cell, colorectal) Baseline medical costs
22
Capitalist Slides
Secondary AnalysisCost/Utilization - Results
Reed et al. (2018) JAMA-OTO
Baseline Characteristics:
2-year 5-year 10-year
Hearing loss No hearing loss Hearing loss No hearing loss Hearing loss No hearing loss
(n=77,207) (n=77,207) (n=22,426) (n=22,426) (n=2,364) (n=2,364)Demographics
Age, mean (sd) 63.80 (9.74) 63.79 (9.70) 61.71 (9.22) 61.70 (9.20) 61.03 (9.30) 61.05 (9.28)Female, N (%) 37,309 (48.3) 37,155 (48.1) 10,792 (48.1) 10,671 (47.6) 1,150 (48.6) 1,130 (47.8)Race, N (%)
Asian 1,707 (2.2) 1,626 (2.1) 385 (1.7) 352 (1.6) 39 (1.6) 34 (1.4)Black 4,367 (5.7) 4,420 (5.7) 1,312 (5.9) 1,373 (6.1) 144 (6.1) 162 (6.9)Hispanic 3,933 (5.1) 4,039 (5.2) 1,061 (4.7) 1,050 (4.7) 89 (3.8) 95 (4.0)Unknown 20,428 (26.5) 20,452 (26.5) 6,282 (28.0) 6,389 (28.5) 605 (25.6) 642 (27.2)White 46,772 (60.6) 46,670 (60.4) 13,386 (59.7) 13,262 (59.1) 1,487 (62.9) 1,431 (60.5)
Region, N (%)Midwest 21,896 (28.4) 21,951 (28.4) 6,903 (30.8) 6,796 (30.3) 861 (36.4) 830 (35.1)Northeast 14,536 (18.8) 14,323 (18.6) 3,966 (17.7) 3,906 (17.4) 418 (17.7) 436 (18.4)South 31,820 (41.2) 31, 929 (41.4) 9,205 (41.0) 9,329 (41.6) 882 (37.3) 899 (38.0)West 8,955 (11.6) 9,004 (11.7) 2,352 (10.5) 2,395 (10.7) 203 (8.6) 199 (8.4)
Net worth, N (%)Unknown 22,874 (29.6) 22,951 (29.7) 6,978 (31.1) 7,137 (31.8) 673 (28.5) 718 (30.4)<$25,000 2,771 (3.6) 2,707 (3.5) 729 (3.3) 682 (3.0) 80 (3.4) 77 (3.3)$24,000-$149,000 7,610 (9.9) 7,447 (9.6) 2,038 (9.1) 1,998 (8.9) 206 (8.7) 185 (7.8)$150,000-$249,000 7,678 (9.9) 7,815 (10.1) 2,047 (9.1) 2,043 (9.1) 195 (8.2) 193 (8.2)$250,000-$499,000 16,404 (21.2) 16,564 (21.5) 4,745 (21.2) 4,738 (21.1) 558 (23.6) 560 (23.7)$500k+ 19,870 (25.7) 19,723 (25.5) 5,889 (26.3) 5,828 (26.0) 652 (27.6) 631 (26.7)
Education, N (%)Less than 12th grade 231 (0.3) 219 (0.3) 39 (0.2) 37 (0.2) ** **High School diploma 14,647 (19.0) 14,568 (18.9) 3,937 (17.6) 3,890 (17.3) 380 (16.1) 386 (16.3)Less than bachelor’s degree 31,981 (41.4) 32,166 (41.7) 9,139 (40.8) 9,072 (40.5) 992 (42.0) 965 (40.8)Bachelor’s degree or more 12,068 (15.6) 11,886 (15.4) 3,621 (16.1) 3,594 (16.0) 444 (18.8) 430 (18.2)Unknown 18,280 (23.7) 18,368 (23.8) 5,690 (25.4) 5,833 (26.0) <546 <585
Medicare, N (%) 24,028 (31.1) 24,028 (31.1) 6,025 (26.9) 6,025 (26.9) 755 (31.9) 755 (31.9)Baseline Utilization
Inpatient stays, mean (sd) 0.14 (0.47) 0.14 (0.43) 0.12 (0.42) 0.12 (0.39) 0.10 (0.34) 0.10 (0.33)Total inpatient days, mean (sd) 0.79 (4.94) 0.82 (4.30) 0.61 (3.31) 0.64 (3.22) 0.54 (2.49) 0.54 (2.36)Outpatient encounters, mean (sd)
18.73 (18.18) 18.63 (17.84) 17.17 (16.07) 17.13 (15.67) 15.55 (14.35) 14.91 (13.33)
ER visits, mean (sd) 0.32 (0.77) 0.32 (0.75) 0.27 (0.69) 0.27 (0.66) 0.24 (0.59) 0.22 (0.54)Medical costs, mean (sd) $8,311.24
($20,645.18)$8,479.90
($19,165.55$7,418.90
($17,586.02)$7,536.63
($15,933.56)$6,365.09
($14,413.20)$6,272.95
($11,928.82)Baseline Comorbidities
Charlson Comorbidity Index, mean (sd) 1.12 (1.71) 1.12 (1.68) 0.89 (1.48) 0.90 (1.47) 0.69 (1.24) 0.68 (1.20)
Acute Myocardial Infarction, N (%)324 (0.4) 301 (0.4) 87 (0.4) 76 (0.3) 13 (0.5) 14 (0.6)
Depression, N (%) 8,358 (10.8) 8,325 (10.8) 2,147 (9.6) 2,109 (9.4) 201 (8.5) 192 (8.1)Dementia, N (%) 2,104 (2.7) 2,189 (2.8) 381 (1.7) 411 (1.8) 14 (0.6) 18 (0.8)Stroke, N (%) 1,963 (2.5) 1,953 (2.5) 466 (2.1) 437 (1.9) 35 (1.5) 30 (1.3)Mild Cognitive Impairment, N (%)
107 (0.1) 113 (0.1) ** ** ** **
Coronary Artery Disease, N (%) 8,744 (11.3) 8,850 (11.5) 2,119 (9.4) 2,195 (9.8) 208 (8.8) 224 (9.5)
23
Capitalist Slides
Secondary AnalysisCost/Utilization - Results
Reed et al. (2018) JAMA-OTO
Post-Match, Unadjusted Health Service Costs and Utilization, HearingLoss vs. No Hearing Loss
2-year 5-year 10-yearHearing
LossNo hearing
loss Hearing Loss No hearing loss Hearing Loss No hearing
loss(n=77,207) (n=77,207) (n=22,426) (n=22,426) (n=2,364) (n=2,364)
Healthcare Outcome Measure
Medical costs, mean (sd) $18,744.36 ($40,628.30)
$14,892.70 ($32,038.23)
$41,386.64 ($64,387.99)
$30,239.23 ($49,259.55)
$70,631.60 ($84,918.08)
$48,198.08 ($60,954.44)
Non-hearing loss Medical Costs, mean (sd)
$18,362.40 ($40,613.22)
$14,892.70 ($32,038.23)
$40,916.95 ($64,371.86)
$30,239.23 ($49,259.55)
$70,075.82 ($84,894.26)
$48,198.08 ($60,954.44)
Inpatient stays, mean (sd) 0.28 (0.78) 0.24 (0.69) 0.62 (1.34) 0.48 (1.08) 1.24 (2.05) 0.86 (1.60)
Inpatient days, mean (sd) 1.57 (6.78) 1.31 (5.43) 3.25 (9.83) 2.50 (8.25) 6.56 (14.81) 4.46 (10.88)
Outpatient visit days, mean (sd)
40.18 (36.49)
32.72 (35.18) 90.76 (72.64) 68.62
(62.21)168.05
($123.25)115.85 (95.37)
Non-hearing loss office visit days, mean (sd)
39.62 (36.17)
32.47 (35.00) 89.69 (71.99) 68.10
(61.76)166.00
(121.14)115.13 (94.79)
ER visits, mean (sd) 0.64 (1.37) 0.52 (1.30) 1.39 (2.85) 1.10 (2.14) 2.61 (3.61) 1.81 (2.77)
30 Day Readmission, N (%) 1,542 (2.0) 1,198 (1.6) 829 (3.7) 646 (2.9) 164 (6.9) 114 (4.8)
24
Capitalist Slides
Secondary AnalysisCost/Utilization - Results
Reed et al. (2018) JAMA-OTO
Difference in Unadjusted Mean Patient Paid, Plan Paid, and Total Costs,Hearing Loss vs. No Hearing Loss
Hearing lossassociated witha 46.5%increase inhealthcarecosts over a 10-year period
25
Capitalist Slides
Secondary AnalysisResults
Reed et al. (2018) JAMA-OTO
Unadjusted Difference in 30-day Readmissions for Subjects withUncorrected Hearing Loss vs. No Hearing Loss
Hearing lossassociated witha 44% increasein risk of 30-dayreadmissionsover 10-years
26
Capitalist Slides
Secondary AnalysisConclusion
Reed et al. (2018) JAMA-OTO
Hearing loss is associated with increase healthcare expenditures andresource utilization over a 10-year period.
Hearing Loss is associated with higher odds of dissatisfaction withmedical care.
Patient-Provider communication as a mechanism?
Limitations: Claims data has inherent limitations
Exposure capture (those with means to access healthcare) Hearing loss individuals in non-hearing loss group No indirect costs (hearing aids?) Residual unmeasured confounding (despite matching)
27
Capitalist Slides
Objectives of Talk
Part 1; Secondary Analyses The impact of hearing loss on health care cost and utilization
measures Hearing Loss and satisfaction: A cross sectional analysis
Part 2; Primary Data Development and feasibility investigation of a systematic strategy to
address hearing loss in the inpatient setting
28
Capitalist Slides
Screening and InterventionBackground
Reed et al. (2018) In-Progress
Development and feasibility investigation of a systematic strategy toaddress hearing loss in the inpatient setting
No universal program to identify and intervene on hearing loss inadults in the hospital system
Many calls for adult hearing screening but most have ignored basicprinciples of implementation science
29
Capitalist Slides
Screening and InterventionBackground
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Implementation Science: Translating evidence into sustainable practice
Current state of hearing screenings for adults:
Run by foreign units (audiology) Single person screening all
Generally from outside Purpose is generally for referral for formal hearing care
Indirect implications Use specialized equipment
Training, time Label patient (puts responsibility on patient) Lack training programs Lack of “buy-in”
30
Capitalist Slides
ENHANCEBackground
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
ENgaging Healthcare to Address Communication Environments
Imbedded within current workflow Universal training end education sessions
Improve fidelity and “buy-in” Purpose is to improve patient-provider communication
Direct implications for staff Onus of communication placed on staff/providers Self-report hearing loss
Minimizes training, time
31
Capitalist Slides
ENHANCEBackground
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
No Hearing Loss
Mild Hearing Loss
Admission:Screen for hearing
loss using self-report as part of
common procedures ≥Moderate
Hearing Loss
No Intervention
Communication Signage
Signage + Amplifier
32
Capitalist Slides
ENHANCEBackground
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
33
Capitalist Slides
ENHANCEBackground
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
34
Capitalist Slides
ENHANCE3-month feasibility
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
From Jan –Mar 2018: Feasibility Trial
Med A and Med B at Bayview Hospital (Community Hospital)
Engage (prior):
1 meeting with Armstrong Institute 2 meetings with ADA compliance office 3 meetings with Aesthetics Committee 3 meetings with Bayview Med A+B administration 5 meetings with Med A +B clinical nurse specialists, charge nurses
Champion: Clinical nurse specialist 6 lunch and learn events with staff (3 each Med A and B)
35
Capitalist Slides
ENHANCE3-month feasibility
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Educate:
6 lunch and learn prior to kick off Materials were printed and distributed to all staff and providers 8 lunch and learn during program (~15-20 minutes)
4 in 2nd week 4 in 4th week
16 check-in huddles (~1-2 minutes) 4 in 1st week 4 in 3rd week 4 in 6th week 4 in 8th week
Amounts to 8 formal education opportunities per shift over period
36
Capitalist Slides
ENHANCE3-month feasibility
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Evaluate : Patient perspective
502 screenings captured (77.9% of all admitted per charge nursenumber reports)
41 indicated form not completed (15 unresponsive patient, 14 refusals,12 time constraints)
543/644 for 84.3% capture rate
37
Capitalist Slides
ENHANCE3-month feasibility
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Evaluate : Patient perspective
Of 502 screened, 60.9% (306) completed discharge form
Screened No HL(n=264)
Mild HL(n=157)
≥ Moderate HL (n=81)
Overall(n=502)
Age, mean (sd) 64.03 years (±7.87)
72.87 years (±7.52)
81.23 years (±6.71)
67.34 years (±4.35)
Device Distributed 0/264 (0%) 7/157 (04.4%) 75/81 (91.4%) 82/502 (16.3%)Discharge Completed 121/264
(45.8%)114/157 (72.6%)
71/81 (87.6%) 306 (60.9%)
Previous communication troubles?Never 23 (19.0%) 17 (14.9%) 3 (04.2%) 43 (14.1%)
Sometimes 71 (58.6%) 42 (36.8%) 11 (15.5%) 124 (40.5%)Most of the time 21(17.3%) 46 (40.4%) 41 (57.7%) 108 (35.3%)
Always 6 (04.9%) 9 (07.9%) 16 (22.5%) 31 (10.1%)Hearing an issue previously in communication?
No 116 (95.8%) 82 (71.9%) 19 (26.8%) 217 (70.9%)Yes 5 (04.1%) 32 (28.1%) 52 (73.2%) 89 (29.7%)
Improved communication during current stay?No difference 21 (17.4%) 3 (02.6%) 4 (05.6%) 28 (09.2%)
Slight Improvement 36 (29.8%) 21 (18.4%) 9 (12.7%) 66 (21.6%)Improved A little 46 (38.0%) 58 (50.9%) 17 (23.9%) 121 (39.5%)
Improved A lot 18 (14.9%) 32 (28.1%) 41 (57.7%) 91 (23.7%)Satisfied with communication during current stay?
Not Satisfied 11 (9.09%) 5 (04.4%) 1 (01.4%) 17 (5.6%)Somewhat Satisfied 12 (9.92%) 13 (11.4%) 4 (05.6%) 29 (9.5%)
Mostly Satisfied 18 (14.9%) 15 (13.2%) 7 (09.9%) 40 (13.1%)Completely Satisfied 80 (66.1%) 81 (71.1%) 59 (83.1%) 220 (71.9%)
See communication program used in other healthcare settings?No 21 (17.4%) 6 (05.3%) 1 (01.4%) 28 (09.2%)
Yes 92 (76.0%) 103 (90.4%) 67 (94.4%) 262 (85.6%)Yes, with changes 8 (06.6%) 5 (04.4%) 3 (04.2%) 16 (5.2%)
38
Capitalist Slides
ENHANCE3-month feasibility
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Evaluate : Provider/Staff Perspective
“Best intervention ever! I normally have a loud voice and some peoplestill can't hear me, but once they put the headphones on, then they canhear. It's nice not loosing your voice :)”
“Such a wonderful program for patients. This has come in handy andpatients truly benefit from this. This has made my job much easier! Thankyou!“
39
Capitalist Slides
ENHANCE3-month feasibility
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Evaluate : Provider/Staff Perspective
18 completed surveyN
egat
ivel
y di
srup
ted
wor
kflo
w
Took
too
long
Mad
e it
easi
er to
com
mun
icat
e w
ith p
atie
nts
Dur
ing
prog
ram
, fou
nd I
was
repe
atin
g m
ysel
f le
ss o
ften
Dur
ing
the
prog
ram
I fo
und
that
pat
ient
s w
ere
less
con
fuse
d w
hen
disc
ussi
ng c
are
I fou
nd th
e pr
ogra
m s
aved
me
time
by
mak
ing
com
mun
icat
ion
easi
er
I fou
nd m
ysel
f usi
ng b
est-p
ract
ice
com
mun
icat
ion
mor
e of
ten
rega
rdle
ss o
f w
heth
er p
atie
nts
had
hear
ing
loss
Pat
ient
s ap
prec
iate
d th
e pr
ogra
m
I fel
t lik
e I n
eede
d m
ore
train
ing
to im
plem
ent
the
prog
ram
I wou
ld li
ke to
see
this
pro
gram
impl
emen
ted
thro
ugho
ut th
e sy
stem
The
hear
ing
scre
enin
g an
d in
terv
entio
n pr
ogra
m h
as v
alue
in th
e m
edic
al s
ettin
g
Strongly Agree0 0 10 6 3 7 3 6 0 8 8
Agree0 1 8 9 10 9 11 11 2 7 9
Neutral3 13 0 2 5 2 3 1 2 3 1
Disagree 8 4 0 1 0 0 1 0 13 0 0
Strongly Disagree 7 0 0 0 0 0 0 0 1 0 0
40
Capitalist Slides
ENHANCEImplications
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Universal Adult Hearing Screening: Move towards acceptance Educating the rest of the medical community Future for objective measures
Professionals in the context of OTC: Raise awareness Potential for knowledge disbursement Establishing a hearing care ecosystem
HCAHPS (the Hospital Consumer Assessment of Healthcare Providersand Systems: Medicare reimbursement Hospital Incentive
41
Capitalist Slides
ENHANCEFuture
Pronovost, Berenholtz, & Needham et al. (2008) JAMA; Reed et al. (2018) In-Progress
Fall 2018: Redesign of materials Integrate demographic variables to calculate hearing loss Webinar training video with quiz
Spring 2018: Mass. General (Boston, MA): (2 floors, pre and post) nurse feedback,
length of stay, HCAHPS Bayview Surgical Units: Process evaluation of new materials and
webinar looking at compliance and retention of knowledge
Summer/Fall 2019: Johns Hopkins East Baltimore: cluster trial, length of stay
42
Capitalist Slides
Special Thanks
Frank Lin, MD PhDJennifer Deal, PhDAmber Willink, PhDJosh Betz, PhDEmily Boss, MDEsther Oh, MD, PhDMegru Liao, MFAEmily Pedersen, MPH
Charlotte Yeh, MD (AARP)Aylin Altan, PhD (OptumLabs)Kevin Frick, AuD, PhD (MEEI, Harvard)
NIH Kl2 – ICTR (Johns Hopkins)Cochlear, Inc (Sydney, Australia)